Efficacy and safety of high doses of safinamide in advanced Parkinson disease

Parkinsonism Relat Disord. 2022 Apr:97:73-74. doi: 10.1016/j.parkreldis.2022.03.010. Epub 2022 Mar 23.

Affiliations

¹ Movement Disorders Unit. Neurology Department, University Hospital Ramón y Cajal, Madrid, Spain. Electronic address: frjorge@salud.madrid.org.
² Movement Disorders Unit. Neurology Department, University Hospital Ramón y Cajal, Madrid, Spain.
³ Movement Disorders Unit. Neurology Department, University Hospital Santa Creu i Sant Pau, Barcelona, Spain.

PMID: 35344893
DOI: 10.1016/j.parkreldis.2022.03.010

No abstract available

Keywords: Clinical global impression of improvement; Dyskinesia; Fluctuating; Safinamide; UPDRS IV.

Publication types

Letter

MeSH terms

Alanine / adverse effects
Alanine / analogs & derivatives
Antiparkinson Agents / adverse effects
Benzylamines / adverse effects
Humans
Levodopa
Parkinson Disease* / complications
Parkinson Disease* / drug therapy

Substances

Antiparkinson Agents
Benzylamines
Levodopa
safinamide
Alanine